- Home
- GLMD
as 07-26-2024 4:00pm EST
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
| Founded: | 2000 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 1.9M | IPO Year: | 2014 |
| Target Price: | N/A | AVG Volume (30 days): | 60.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.26 - $1.21 | Next Earning Date: | 08-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Galmed Pharmaceuticals Ltd. News
GLMD Breaking Stock News: Dive into GLMD Ticker-Specific Updates for Smart Investing
PR Newswire
4 months ago
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
PR Newswire
4 months ago
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
GlobeNewswire
6 months ago
Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
GlobeNewswire
6 months ago
ClimateRock and GreenRock Announce Filing of a Registration Statement in Connection with Proposed Business Combination
Market Exclusive
6 months ago
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
PR Newswire
6 months ago
EZGO ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2023
ACCESSWIRE
6 months ago
SOBRsafe CEO Dave Gandini to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
GlobeNewswire
6 months ago
BTCS Issues Shareholder Letter Reflecting on 2023 and Outlook for 2024
Compare GLMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GLMD Galmed Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.